- Home
- SNTI vs CLDI Comparison
SNTI vs CLDI Comparison
Compare SNTI & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- CLDI
- Stock Information
- Founded
- SNTI 2016
- CLDI 2014
- Country
- SNTI United States
- CLDI United States
- Employees
- SNTI N/A
- CLDI N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNTI Health Care
- CLDI Health Care
- Exchange
- SNTI Nasdaq
- CLDI Nasdaq
- Market Cap
- SNTI 19.1M
- CLDI 18.1M
- IPO Year
- SNTI N/A
- CLDI N/A
- Fundamental
- Price
- SNTI $4.67
- CLDI $0.89
- Analyst Decision
- SNTI Strong Buy
- CLDI Strong Buy
- Analyst Count
- SNTI 1
- CLDI 3
- Target Price
- SNTI $12.00
- CLDI $16.67
- AVG Volume (30 Days)
- SNTI 115.8K
- CLDI 1.2M
- Earning Date
- SNTI 11-14-2024
- CLDI 03-14-2025
- Dividend Yield
- SNTI N/A
- CLDI N/A
- EPS Growth
- SNTI N/A
- CLDI N/A
- EPS
- SNTI N/A
- CLDI N/A
- Revenue
- SNTI N/A
- CLDI N/A
- Revenue This Year
- SNTI $11.52
- CLDI N/A
- Revenue Next Year
- SNTI $78.57
- CLDI N/A
- P/E Ratio
- SNTI N/A
- CLDI N/A
- Revenue Growth
- SNTI N/A
- CLDI N/A
- 52 Week Low
- SNTI $1.52
- CLDI $0.73
- 52 Week High
- SNTI $16.94
- CLDI $16.80
- Technical
- Relative Strength Index (RSI)
- SNTI 56.65
- CLDI 32.62
- Support Level
- SNTI $3.72
- CLDI $0.83
- Resistance Level
- SNTI $4.93
- CLDI $0.95
- Average True Range (ATR)
- SNTI 0.46
- CLDI 0.12
- MACD
- SNTI 0.01
- CLDI -0.03
- Stochastic Oscillator
- SNTI 81.82
- CLDI 11.29
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.